Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Research|December 4, 2001
A new mouse model for evaluating the immunotherapy of human colorectal cancerH Hörig, A Wainstein, L Long, et al.
Cellular Immunology|February 1, 1993
On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activityG C Spagnoli, A Juretic, E Schultz-Thater, et al.
Cellular Immunology|September 1, 1994
Generation of lymphokine-activated killer activity in rodents but not in humans is nitric oxide dependentA Juretic, G C Spagnoli, K von Bremen, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|November 1, 1993
Glutamine peptide-supplemented long-term total parenteral nutrition: effects on intracellular and extracellular amino acid patterns, nitrogen economy, and tissue morphology in growing ratsR Babst, H Hörig, P Stehle, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 1, 1996
Nitric oxide-independent inhibitory effects of L-arginine analog NG-monomethy-L-arginine on the generation of interleukin-2 activated cytotoxic activity in humansA Juretić, G C Spagnoli, H Hörig, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 5, 2001
Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytesG A Kicska, L Long, H Hörig, et al.
Immunology|June 1, 1995
Tyrosine kinase-dependent and -independent events induced by interleukin-2 stimulation: interleukin-2-mediated NO production required for the induction of lymphokine-activated killer cell activity in rat splenocytes is tyrosine kinase independentA Juretic, G C Spagnoli, H Hörig, et al.
Molecular Immunology|November 21, 1998
Point mutations in the beta chain CDR3 can alter the T cell receptor recognition pattern on an MHC class I/peptide complex over a broad interface areaE C Goyarts, Z Vegh, A M Kalergis, et al.
Cancer Immunology, Immunotherapy : CII|November 25, 2000
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory moleculeH Hörig, D S Lee, W Conkright, et al.
Pageof 2